T‐Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma
International Journal of Breast Cancer · 2026-01 · 2026 (1)
DOI: 10.1155/ijbc/3747828 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Breast Cancer, online erschienen am 15.04.2026. Verfasst von Mio Yamaguchi-Tanaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan, tohoku.ac.jp. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Therapeutic resistance, including resistance to endocrine therapy in ER‐positive tumors and to chemotherapy in aggressive subtypes, remains a major clinical challenge in breast cancer. T‐cell immunoglobulin and mucin domain 1 (Tim1), a Type I transmembrane glycoprotein, has been reported to be aberrantly expressed in various cancer cells and contribute to tumor progression. However, its clinical significance in breast cancer and association with therapy resistance remain largely unclear.
Methods
We investigated Tim1 expression by immunohistochemistry in 116 breast carcinoma tissues and analyzed its correlation with clinicopathological parameters and clinical outcomes according to chemotherapy and endocrine therapy status.
Results
Tim1 immunoreactivity was detected in the cytoplasm and cell membranes of breast carcinoma cells but was negligible in the normal breast epithelium. Tim1 expression was significantly associated with pathological T factor, lymph node metastasis, histological grade, and Ki67 labeling index. Tim1 immunoreactivity was significantly correlated with an increased risk of recurrence, and multivariate analyses demonstrated Tim1 as an independent adverse prognostic factor for disease‐free survival. In addition, Tim1 remained correlated with the risk of recurrence in patients who had received chemotherapy or endocrine therapy.
Conclusions
Tim1 might be an important therapeutic target for improving therapy in breast cancer patients and could be a strong adverse prognostic factor associated with therapeutic resistance.
Autor:innen und Institutionen
- Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan, tohoku.ac.jp.
- Department of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan, tohoku.ac.jp.
- Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan, tohoku.ac.jp.
- Department of Pathology, Tohoku University Hospital, Sendai, Miyagi, Japan, tohoku.ac.jp.
ORCID-Profile: Mio Yamaguchi-Tanaka, Minoru Miyashita
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yamaguchi-Tanaka, M., Takagi, K., Sawafuji, M., Sato, A., Nakamura, K., Miki, Y., Miyashita, M., & Suzuki, T. (2026). T‐Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma. International Journal of Breast Cancer, 2026(1). https://doi.org/10.1155/ijbc/3747828
Vancouver
Yamaguchi-Tanaka M, Takagi K, Sawafuji M, Sato A, Nakamura K, Miki Y, et al. T‐Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma. International Journal of Breast Cancer. 2026;2026(1). doi:10.1155/ijbc/3747828
BibTeX
@article{YamaguchiTanaka2026,
author = {Yamaguchi-Tanaka, Mio and Takagi, Kiyoshi and Sawafuji, Mai and Sato, Ai and Nakamura, Kanoko and Miki, Yasuhiro and Miyashita, Minoru and Suzuki, Takashi},
title = {T‐Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma},
journal = {International Journal of Breast Cancer},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijbc/3747828}
}
EUVIMED